PressOctober 26, 2023 Safe Supply Streaming Co. Ltd. Announces Appointment of Ronan Levy as President
PressOctober 25, 2023 ATMA Welcomes Dr. Scott Shannon, MAPS MDMA Phase 3 Principal Investigator, to Expand Its’ Clinical Training Expertise in MDMA-Assisted Therapy
PressOctober 25, 2023 First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)
PressOctober 25, 2023 The Healing Company’s Chopra and Swan Hellenic Announce Exclusive, Multi-Year Partnership With Launch of Well-Being Travel Experience “Explore & Restore”
PressOctober 25, 2023 Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
PressOctober 23, 2023 FSD Pharma Inc. Announces Filing in Connection with Proposed Arrangement with Celly Nu
PressOctober 23, 2023 Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
BlogOctober 20, 2023 Brain & Behavior Research Foundation Awards $10.2 Million in Young Investigator Grants to 150 Mental Health Scientists
Psychedelic NewsOctober 20, 2023 Roland Griffiths: An Extraordinary Life & Legacy in Psychedelic Research
PressOctober 19, 2023 Red Light Holland’s Fully Owned Subsidiary, Radix Motion, Granted Patent for 3D Movement Data and AI Innovations
PressOctober 19, 2023 Pioneers and Innovators in Psilocybin Treatments and How Big Pharma wants in on the Psychedelic Sector
PressOctober 18, 2023 Mushrooms Inc (OTC:MSRM) Announces Full Patent Filing for Groundbreaking Mycelium Technology Providing Bacterial Detection and Nutrient Delivery
PressOctober 18, 2023 Lucy Scientific Discovery’s Alternative Mental Health Treatments to Provide Opportunity to Improve Mental Health
PressOctober 18, 2023 Mydecine Innovations Group gearing up for human trials after completing Aquis listing
PressOctober 17, 2023 Diamond Therapeutics Announces First Patient Enrolled in FDA-authorized Study Evaluating Low-Dose Psilocybin in Human Subjects with Demoralization
PressOctober 17, 2023 Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
